Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 1 of 1 entries
Sorted by: Best Match Show Resources per page
The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man.

Expert opinion on investigational drugs

McDowell G, Nicholls DP.
PMID: 15992061
Expert Opin Investig Drugs. 1999 Jan;8(1):79-84. doi: 10.1517/13543784.8.1.79.

Candoxatril (UK-79300) is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of (+/-)candoxatrilat (UK-69578), a potent neutral endopeptidase (NEP) inhibitor. This article describes the rationale behind the use of such a drug in the treatment of chronic heart...

Cite
McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999;8(1):79-84doi: 10.1517/13543784.8.1.79.
McDowell, G., & Nicholls, D. P. (1999). The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert opinion on investigational drugs, 8(1), 79-84. https://doi.org/10.1517/13543784.8.1.79
McDowell, G, and Nicholls, D P. "The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man." Expert opinion on investigational drugs vol. 8,1 (1999): 79-84. doi: https://doi.org/10.1517/13543784.8.1.79
McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999 Jan;8(1):79-84. doi: 10.1517/13543784.8.1.79. PMID: 15992061.
Copy Download .nbib Format: NLM
Showing 1 to 1 of 1 entries